Can a cheaper, easier drug keep CML at bay after stronger treatment?
NCT ID NCT01316250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether people with chronic myeloid leukemia (CML) who had a good response to the drug nilotinib could switch to imatinib to maintain that response. The goal was to see if imatinib could keep the cancer under control while being easier to take and less expensive. Thirteen newly diagnosed adults participated in this small trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American University of Beirut Medical Center
Beirut, Lebanon